AusperBio Announces $37 Million Series A Financing to Advance Hepatitis B Cure Candidate AHB-137 and Expand Med-Oligo™ Platform

Jul 15, 2024 09:50 CST Updated 09:50

AusperBio

Biological Vaccine and Nucleic Acid Drug Developer

InnoPinnacle Fund

Early-Stage Investment Institutions

YuanBio Venture Capital

Venture Capital Institution

Hankang Capital

Biopharmaceutical Venture Capital Fund

Qiming Venture Partners

Healthcare Investment Institutions

▎WuXi AppTec Content Team Report

Today's News (July 15), AusperBio (Hangzhou Haobo Pharmaceutical Co., Ltd. and AusperBio Therapeutics) announced that it has recently completed$37 Million Series A Financing. This round of financing was led byInnoPinnacle Fund Leads Additional Investment，YuanBio Venture Capital, Shanghai Hankang Private Equity Fund Management Co., Ltd., Qiming Venture Partners, and Gongqingcheng Genesis Investment Management Co., Ltd. jointly participated.The proceeds from this round of financing will be mainly used to rapidly advance the Phase 2 clinical trial of AusperBio's potential cornerstone drug for hepatitis B cure, AHB-137, exploration of combination therapy regimens, CMC production, and a series of other development activities. Additionally, the funds will also be utilized to expand the proprietary Med-Oligo™ technology platform and its product pipeline.

Public information shows that AusperBio is an innovative biopharmaceutical company with a global presence and at the clinical stage.Committed toRevolutionizing Hepatitis B Cure Therapies, Leading Oligonucleotide Technology Innovation, with its proprietary Med-Oligo™ ASO platform and highly efficient targeted delivery technology, focuses on transformative ASO therapies for applications in areas such as viral infections, metabolic diseases, genetic disorders, and immune-related conditions to improve patients' lives.

Dr. Guozheng Cheng, Co-founder and CEO of AusperBio, said"We are extremely honored to complete this important financing under the current market environment. This round of financing not only signifies recognition of our R&D achievements but also provides significant momentum for the next chapter of AusperBio. The successful completion of this financing, along with AHB-137 recently receiving approval from the CDE to be designated as a breakthrough therapy, allows us to further accelerate the clinical development of AHB-137."

Dr. Yang Chengyong, Co-founder and CSO of AusperBio, stated:"We are deeply honored to collaborate with many outstanding investment institutions, and we sincerely appreciate their support and trust. AusperBio integrates cutting-edge oligonucleotide technology with highly efficient and precise targeted delivery technology, successfully developing AHB-137 under its self-developed Med-Oligo™ platform. The positive Phase 1 clinical data for this drug recently attracted significant attention at the European Association for the Study of the Liver (EASL) Annual Meeting, marking our international leadership in the field of HBV functional cure. This round of financing will further advance the clinical research of AHB-137, benefiting patients worldwide sooner and creating greater value for society."

Dr. Dechao Yu, Founder, Chairman and CEO of Innovent Biologics, and Founding Managing Partner of InnoPinnacle FundSaid: "Following our initial investment in AusperBio in 2022, we have continued to lead this round of financing. Over the past two years, the company's core pipeline has made rapid progress, and the efficacy and safety data from Phase 1 clinical trials of AHB-137 have demonstrated significant potential for functional cure. We look forward to AusperBio, under the leadership of Dr. Guozheng Cheng and Dr. Chengyong Yang, bringing breakthrough treatments to hepatitis B patients worldwide as soon as possible."

References:

[1] AusperBio Completes $37 Million Series A Financing, Accelerating Revolutionary HBV Cure Therapies. Retrieved July 15 , 2024, from https://cn.ausperbio.com/company.html

This article was compiled and edited by the content team of WuXi AppTec based on publicly available information., welcome to share on personal WeChat Moments. RepostingFor authorization and other cooperation needs, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.